Article Text

Download PDFPDF
Role of digital health in detection and management of atrial fibrillation
  1. James E Tooley,
  2. Marco Valentin Perez
  1. Cardiovascular Medicine, Stanford University, Stanford, California, USA
  1. Correspondence to Dr Marco Valentin Perez, Cardiovascular Medicine, Stanford University, Stanford, California 94305, USA; mvperez{at}stanford.edu

Abstract

Atrial fibrillation is a common arrhythmia associated with significant morbidity, mortality and decreased quality of life. Mobile health devices marketed directly to consumers capable of detecting atrial fibrillation through methods including photoplethysmography, single-lead ECG as well as contactless methods are becoming ubiquitous. Large-scale screening for atrial fibrillation is feasible and has been shown to detect more cases than usual care—however, controversy still exists surrounding screening even in older higher risk populations. Given widespread use of mobile health devices, consumer-driven screening is happening on a large scale in both low-risk and high-risk populations. Given that young people make up a large portion of early adopters of mobile health devices, there is the potential that many more patients with early onset atrial fibrillation will come to clinical attention requiring possible referral to genetic arrythmia clinic. Physicians need to be familiar with these technologies, and understand their risks, and limitations. In the current review, we discuss current mobile health devices used to detect atrial fibrillation, recent and upcoming trials using them for diagnosis of atrial fibrillation, practical recommendations for patients with atrial fibrillation diagnosed by a mobile health device and special consideration in young patients.

  • atrial fibrillation
  • telemedicine
  • stroke

Statistics from Altmetric.com

Footnotes

  • Contributors This review was conducted solely by JET and MVP. JET wrote the first draft of this manuscript.

  • Funding This study was funded by National Heart, Lung, and Blood Institute (1R01HL136390-01).MVP Grant Funding (NHLBI/NIH, Apple Inc.), Consultancy (Apple Inc., Biotronik, Boston Scientific, AltaThera, Feather Health), Equity (Feather Health).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.